Semaglutide, a GLP-1 receptor agonist approved by the FDA for type 2 diabetes and chronic weight management, can cause fatigue through several mechanisms
Another of the study's authors, Professor Francois Venter at the University of Witwatersrand in South Africa, said drugs to treat HIV, TB, malaria, and hepatitis are now available at prices close to production costs but still sufficient for generic manufacturers to operate
This is especially important given that severe dehydration from GI side effects can occasionally cause kidney complications
Semaglutide reduces these inflammatory markers through multiple mechanisms: weight loss decreases fat tissue (a major source of inflammatory compounds), improved glucose control reduces glycation stress, and direct GLP-1 signaling in immune cells dampens pro-inflammatory pathways
Common side effects include nausea, vomiting, diarrhoea, constipation, abdominal discomfort, bloating, headache and fatigue